Remove Cardiology Remove Medicine Remove Research
article thumbnail

UK regulator backs Amarin’s cardiology drug Vazkepa

pharmaphorum

Amarin’s Vazkepa cardiology drug has been backed by the UK’s drugs regulator, following approval in Europe at the end of March. . The Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce risk of cardiovascular events in high-risk patients.

article thumbnail

Integrating Bioanalytical Automation, Biomarkers, Pharmacogenomics, & Cost-Effective Strategies

Worldwide Clinical Trials

Technological advancements have fostered novel drugs and improved precision medicine, suggesting an increased trend of R&D in this direction. We support efficacy markers, safety biomarkers, diagnostic biomarkers, and pharmacodynamic (PD) markers, addressing diverse therapeutic areas such as neurology, oncology, immunology, and cardiology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gender parity & heart failure research: Female authors could mean more female participants

Scienmag

The […].

article thumbnail

Alert banners dramatically increase prescribing rates of life-saving heart failure medication

Medical Xpress

An automated system that flags which patients could most benefit from an underused yet life-saving cardiology drug more than doubled new prescriptions, according to a pilot program test by researchers at NYU Grossman School of Medicine.

article thumbnail

Nuclear medicine bone scan study identifies prevalence and outcomes of cardiac amyloidosis

Medical Xpress

Published in The Journal of Nuclear Medicine, this research is among the first of its kind to identify the prevalence and outcomes of cardiac amyloidosis among the general population.

article thumbnail

Cardiology Clinical Trials with Dr. Gregg Stone

Clinical Trial Podcast

To learn more about this important field of cardiovascular clinical research, I invited Dr. Gregg Stone on the podcast. With an H-index of 202, Dr. Stone has been recognized in Nature Medicine as one of the most prolific authors in science, and by the Web of Science as among the top 0.01% of cited researchers in science.

article thumbnail

Grand Rounds December 15, 2023: Diversifying Clinical Trials: A Path Forward (Roxana Mehran, MD, FACC, FAHA, MSCAI, FESC)

Rethinking Clinical Trials

Diversity in clinical trials is important for generalizability of results, to provide equal opportunities, practice precision medicine, tailor practical guidelines, improve public health outcomes, detect potential differences in safety and efficacy, and to address health disparities. CVD is the leading cause of mortality in women.